Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Clin Res Hepatol Gastroenterol Retrieve available abstracts of 293 articles: HTML format

Single Articles

April 2024
1. LI Y, Guo Y, Tan S
   Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease.
   Clin Res Hepatol Gastroenterol. 2024;48:102320.
   PubMed     Abstract available
   
   
   
2. ORUC M, Gedik ME, Uner M, Ulug E, et al
   Effectiveness of metformin for the reversal of cold-ischemia-induced damage in hepatosteatosis.
   Clin Res Hepatol Gastroenterol. 2024;48:102314.
   PubMed     Abstract available
   
   
   
3. JI J, Zhang Z, Hou Z, Qiu G, et al
   Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
   Clin Res Hepatol Gastroenterol. 2024;48:102313.
   PubMed     Abstract available
   
   
   March 2024
4. NDHLOVU E, Zhang BX, Chen XP, Zhu P, et al
   Thermal ablation for hepatic tumors in high-risk locations.
   Clin Res Hepatol Gastroenterol. 2024;48:102300.
   PubMed     Abstract available
   
   
   
5. LI B, Ren ZW, Zhang C, Yu XX, et al
   Computed tomography-guided percutaneous cryoablation and microwave ablation in the treatment of perivascular hepatocellular carcinoma: A comparative study with propensity score matching.
   Clin Res Hepatol Gastroenterol. 2024;48:102298.
   PubMed     Abstract available
   
   
   
6. RAN D, Xin C, Ma Y, Lu Y, et al
   Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components.
   Clin Res Hepatol Gastroenterol. 2024;48:102302.
   PubMed     Abstract available
   
   
   
7. CHEN F, Chen C, Zhang Y, Jiang L, et al
   Bilateral optic atrophy in Wilson disease: A case report and literature review.
   Clin Res Hepatol Gastroenterol. 2024;48:102299.
   PubMed     Abstract available
   
   
   
8. AN Y, Xia Y, Wang Z, Jin GZ, et al
   Clinical significance of ribosome production factor 2 homolog in hepatocellular carcinoma.
   Clin Res Hepatol Gastroenterol. 2024;48:102289.
   PubMed     Abstract available
   
   
   
9. HAYAT HMS, Naeem H
   Aspirin for non alcoholic fatty liver disease: Promising but inconclusive-A letter to the editor.
   Clin Res Hepatol Gastroenterol. 2024;48:102286.
   PubMed    
   
   
   
10. HOOSHMAND GHARABAGH L, Shargh A, Mohammad Hosseini Azar MR, Esmaeili A, et al
    Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102279.
    PubMed     Abstract available
    
    
    February 2024
11. GUO J, Shi L, Sun Y
    Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102284.
    PubMed     Abstract available
    
    
    
12. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    PubMed     Abstract available
    
    
    
13. MEJAIT A, Roux C, Soret M, Larrey E, et al
    Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
    Clin Res Hepatol Gastroenterol. 2024;48:102282.
    PubMed     Abstract available
    
    
    
14. QI X, Liu L
    The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features.
    Clin Res Hepatol Gastroenterol. 2024;48:102273.
    PubMed     Abstract available
    
    
    
15. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    PubMed     Abstract available
    
    
    
16. OBADIA MA, Woimant F, Tuppin P, Debray D, et al
    Reply to "Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the National health insurance database".
    Clin Res Hepatol Gastroenterol. 2024;48:102265.
    PubMed    
    
    
    January 2024
17. KUMAR J, Mohsin S, Hasan M, Bilal AR, et al
    Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102261.
    PubMed     Abstract available
    
    
    
18. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    PubMed     Abstract available
    
    
    
19. BAEK KW, Won JH, Xiang YY, Woo DK, et al
    Exercise intensity impacts the improvement of metabolic dysfunction-associated steatotic liver disease via variations of monoacylglycerol O-acyltransferase 1 expression.
    Clin Res Hepatol Gastroenterol. 2024;48:102263.
    PubMed     Abstract available
    
    
    
20. CHEVAL M, Latrasse M, Tran Ba S, Robbe G, et al
    Extensive cortical and thalamic FLAIR hypersignals in a patient with suspected hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2024;48:102258.
    PubMed    
    
    
    
21. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    PubMed    
    
    
    December 2023
22. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    PubMed     Abstract available
    
    
    
23. LASSAILLY G, Ningarhari M, Dumortier J, Lafforgue C, et al
    Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;48:102266.
    PubMed     Abstract available
    
    
    
24. JIANG J, Hu Y, Fang D, Luo J, et al
    Glutamine synthetase and hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102248.
    PubMed     Abstract available
    
    
    
25. ZHANG X, Li X, Xiong X
    Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Clin Res Hepatol Gastroenterol. 2023;47:102230.
    PubMed     Abstract available
    
    
    
26. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    PubMed     Abstract available
    
    
    
27. TAMILMANI P, Sathibabu Uddandrao VV, Chandrasekaran P, Saravanan G, et al
    Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-alpha/AMPK and Nrf-2/HO-1 signaling pathways.
    Clin Res Hepatol Gastroenterol. 2023;47:102231.
    PubMed     Abstract available
    
    
    
28. PEI E, Wang H, Li Z, Xie X, et al
    Endoplasmic reticulum stress inhibitor may substitute for sleeve gastrectomy to alleviate metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102229.
    PubMed     Abstract available
    
    
    
29. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    PubMed     Abstract available
    
    
    
30. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    PubMed     Abstract available
    
    
    November 2023
31. ALLAIRE M, Roux C, Akhavan S, Lebray P, et al
    Difficulties in assessing portal hypertension in case of HVB-HVD co infection.
    Clin Res Hepatol Gastroenterol. 2023;47:102213.
    PubMed    
    
    
    
32. MUTANEN A, Pakarinen MP
    Featuring molecular regulation of bile acid homeostasis in pediatric short bowel syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102220.
    PubMed     Abstract available
    
    
    October 2023
33. DENG K, Yang F, Liu X, Deng M, et al
    Adult Kasabach-Merritt syndrome secondary to hepatic angiosarcoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102211.
    PubMed    
    
    
    
34. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    PubMed     Abstract available
    
    
    
35. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    PubMed     Abstract available
    
    
    
36. DI GIORGIO A, Sciveres M, Fuoti M, Sonzogni A, et al
    Treatment with an ileal bile acid transporter inhibitor in patients with TJP2 deficiency.
    Clin Res Hepatol Gastroenterol. 2023;47:102185.
    PubMed     Abstract available
    
    
    
37. BOILLOT O, Guillaud O, Wischlen E, Ruiz M, et al
    Determinants of early surgical complications after pediatric liver transplantation: A single center/single surgeon experience over 20 years.
    Clin Res Hepatol Gastroenterol. 2023;47:102222.
    PubMed     Abstract available
    
    
    August 2023
38. LU M, Zhu M, Li H, Wang Q, et al
    Factors associated with discordance in the assessment of fibrosis stage between transient elastography and liver biopsy in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102183.
    PubMed     Abstract available
    
    
    
39. TANG Y, Zhong H, Wang Y, Wu J, et al
    Efficacy of microwave ablation versus radiofrequency ablation in the treatment of colorectal liver metastases: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102182.
    PubMed     Abstract available
    
    
    
40. MAMANDIPOOR B, Wernly S, Semmler G, Flamm M, et al
    Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study.
    Clin Res Hepatol Gastroenterol. 2023;47:102181.
    PubMed     Abstract available
    
    
    
41. CALLERI A, Alessandria C
    Renal damage in Hepatorenal Syndrome: A still unsolved issue.
    Clin Res Hepatol Gastroenterol. 2023;47:102178.
    PubMed     Abstract available
    
    
    
42. BANDYOPADHYAY S, Samajdar SS, Das S
    Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102174.
    PubMed     Abstract available
    
    
    
43. GUO B, Zhou Y, Liu Z, Chen Q, et al
    TACE plus PD-1 successfully achieves conversion therapy for unresectable HCC with multiple macrovascular invasion: Case report.
    Clin Res Hepatol Gastroenterol. 2023;47:102169.
    PubMed    
    
    
    
44. PENA LC, Couto CA, Correa BHM, Ferrua LFQ, et al
    Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102163.
    PubMed     Abstract available
    
    
    
45. LI ZX, Zhang QF, Huang JM, Huang SJ, et al
    Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102165.
    PubMed     Abstract available
    
    
    
46. ISMAIEL A, Hosiny BE, Ismaiel M, Leucuta DC, et al
    Waist to height ratio in nonalcoholic fatty liver disease - Systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102160.
    PubMed     Abstract available
    
    
    
47. WAN W, Zhang H, Ji T, Zhang L, et al
    Optimal treatment strategy for recurrent hepatocellular carcinoma based on recurrence time and tumor size: A propensity score matching study.
    Clin Res Hepatol Gastroenterol. 2023;47:102157.
    PubMed     Abstract available
    
    
    
48. ALOYSIUS MM, Iskander P, Ahmed K, Asija U, et al
    Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data.
    Clin Res Hepatol Gastroenterol. 2023;47:102162.
    PubMed     Abstract available
    
    
    
49. YANG Y, Li X, Zhao X, Liu Y, et al
    Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study.
    Clin Res Hepatol Gastroenterol. 2023;47:102150.
    PubMed     Abstract available
    
    
    
50. LU Y, Liang L, Lu WF, Cheng J, et al
    The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102147.
    PubMed     Abstract available
    
    
    
51. XU J, Shao R, Zhang X, Yao D, et al
    Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
    Clin Res Hepatol Gastroenterol. 2023;47:102149.
    PubMed     Abstract available
    
    
    June 2023
52. WANG X, Xu GH, Yu J, Li H, et al
    When cirrhosis meets paroxysmal nocturnal hemoglobinuria: What kind of "fireworks" scenario will occur?
    Clin Res Hepatol Gastroenterol. 2023;47:102173.
    PubMed    
    
    
    
53. GIUDICELLI H, Roux C, Monsel A, Conti F, et al
    Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation.
    Clin Res Hepatol Gastroenterol. 2023 Jun 19:102167.
    PubMed    
    
    
    May 2023
54. WISCHLEN E, Laverdure N, Erard D, Rohmer B, et al
    Iterative antibody-induced bile salt export pump deficiency after successive liver transplantations successfully treated with plasmapheresis and rituximab.
    Clin Res Hepatol Gastroenterol. 2023;47:102139.
    PubMed     Abstract available
    
    
    
55. MATHURIN P, de Zelicourt M, Laurendeau C, Dhaoui M, et al
    Treatment patterns, risk factors and outcomes for patients with newly diagnosed hepatocellular carcinoma in France: A retrospective database analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102124.
    PubMed     Abstract available
    
    
    
56. RAVAIOLI F, Berger A, Farcau O, Colecchia A, et al
    Individual and population screening of varices needing treatment by a simple, safe and accurate test.
    Clin Res Hepatol Gastroenterol. 2023;47:102123.
    PubMed     Abstract available
    
    
    
57. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    PubMed     Abstract available
    
    
    
58. HAMEED I, Hayat J, Marsia S, Samad SA, et al
    Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102111.
    PubMed     Abstract available
    
    
    
59. BARAKAT LA, Elsergany AR, Ghattas MH, Mahsoub N, et al
    Relationship between interferon-induced transmembrane protein 3 and matrix metalloproteinase-9 gene polymorphisms in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102110.
    PubMed     Abstract available
    
    
    
60. LAZO-DE-LA-VEGA-MONROY ML, Preciado-Puga MD, Ruiz-Noa Y, Salum-Zertuche M, et al
    Correlation of the pediatric metabolic index with NAFLD or MAFLD diagnosis, and serum adipokine levels in children.
    Clin Res Hepatol Gastroenterol. 2023;47:102137.
    PubMed     Abstract available
    
    
    
61. MEURER A, Antoni C, Ebert MP, Trimborn A, et al
    Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid-case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102130.
    PubMed     Abstract available
    
    
    April 2023
62. SASAKI M, Sato Y, Nakanuma Y
    An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2023;47:102106.
    PubMed     Abstract available
    
    
    
63. DUAN Y, Hou X, Guo J, Li H, et al
    D-dimer for assessment of treatment response, and survival to drug-eluting beads transarterial chemoembolization in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102096.
    PubMed     Abstract available
    
    
    March 2023
64. HARING MPD, de Haas RJ, van Vilsteren FGI, Klaase JM, et al
    Variation in the management of benign liver tumors: A European survey and case vignette study.
    Clin Res Hepatol Gastroenterol. 2023;47:102094.
    PubMed     Abstract available
    
    
    
65. CAO L, Qu N, Wang X, Chen L, et al
    The function of long non-coding RNA in non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102095.
    PubMed     Abstract available
    
    
    February 2023
66. IANNONE G, Pompili E, Renzulli M, Caraceni P, et al
    A case of peri-stomal ectopic variceal bleeding in a patient with decompensated cirrhosis treated with TIPS placement.
    Clin Res Hepatol Gastroenterol. 2023 Feb 24:102098.
    PubMed     Abstract available
    
    
    
67. JENVRIN A, Galletto-Pregliasco A, Audureau E, Pujals A, et al
    Intentional R1 resection of liver metastases: A new treatment paradigm for patients with advanced colorectal cancer based on a propensity score-matched case-control analysis.
    Clin Res Hepatol Gastroenterol. 2023 Feb 18:102097.
    PubMed     Abstract available
    
    
    
68. JI PT, Wang XY
    Clinical application study on miR-98-5p as a prognostic biomarker in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2023;47:102077.
    PubMed     Abstract available
    
    
    
69. ZHANG L, Zhang X, Li Q, Makamure J, et al
    Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.
    Clin Res Hepatol Gastroenterol. 2023;47:102071.
    PubMed     Abstract available
    
    
    
70. XIONG W, Qian Z, Mao X, Li J, et al
    T lymphocyte-mediated pyroptosis: A new regulatory mechanism in non-viral liver disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102070.
    PubMed     Abstract available
    
    
    
71. MURALI AR, Prakash S, Sanchez AJ
    Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients().
    Clin Res Hepatol Gastroenterol. 2023;47:102066.
    PubMed     Abstract available
    
    
    
72. ALLAIRE M, Manfredi S, Lerosey L, Ganne-Carrie N, et al
    Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
    Clin Res Hepatol Gastroenterol. 2023;47:102059.
    PubMed     Abstract available
    
    
    
73. ASGARZDEH A, Habibzadeh S, Asghariazar V, Safarzadeh E, et al
    Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination.
    Clin Res Hepatol Gastroenterol. 2023;47:102028.
    PubMed    
    
    
    January 2023
74. BECCHETTI C, Lange NF, Delgado MG, Bronnimann MP, et al
    2D shear wave elastography of the rectus femoris muscle in patients with cirrhosis: feasibility and clinical findings. A pilot study.
    Clin Res Hepatol Gastroenterol. 2023 Jan 16:102080.
    PubMed     Abstract available
    
    
    
75. LIU L, Sun S, Li X
    LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation.
    Clin Res Hepatol Gastroenterol. 2023;47:102067.
    PubMed     Abstract available
    
    
    
76. TIAN H, Zhang K, Hui Z, Ren F, et al
    Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019.
    Clin Res Hepatol Gastroenterol. 2023;47:102068.
    PubMed     Abstract available
    
    
    
77. DU F, Zhang L, Zhang Y, Fan H, et al
    Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102069.
    PubMed     Abstract available
    
    
    
78. ZHANG P, Dong X, Zhang W, Wang S, et al
    Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Clin Res Hepatol Gastroenterol. 2023;47:102063.
    PubMed     Abstract available
    
    
    
79. HU L, Zheng Y, Lin J, Shi X, et al
    Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102061.
    PubMed     Abstract available
    
    
    
80. WANG M, Sun L, Han X, Ren J, et al
    The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Clin Res Hepatol Gastroenterol. 2023;47:102060.
    PubMed     Abstract available
    
    
    
81. YANG Y, Wang Y, Wang C, Wu S, et al
    Macrophages and derived-TNF-alpha promote lipopolysaccharide-induced upregulation of endogenous beta-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation.
    Clin Res Hepatol Gastroenterol. 2023;47:102062.
    PubMed     Abstract available
    
    
    
82. OKADA S, Kashima K, Okada K, Okada J, et al
    Aging affects FIB-4 index in the general population without pre-existing diseases: Analysis of a cohort of healthy individuals who underwent annual health checkups for 10 consecutive years.
    Clin Res Hepatol Gastroenterol. 2023;47:102058.
    PubMed    
    
    
    
83. ZOU CY, Sun Y, Liang J
    Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis(,).
    Clin Res Hepatol Gastroenterol. 2023;47:102053.
    PubMed     Abstract available
    
    
    
84. YANG XS, Li XH, Yan CY, Wei JP, et al
    Different 18F-FDG imaging: A rare case of liver multiple carcinomas.
    Clin Res Hepatol Gastroenterol. 2023;47:102050.
    PubMed     Abstract available
    
    
    December 2022
85. LUO QQ, Wang T, Zhang KH
    New indexes derived from routine blood tests and their clinical application in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:102043.
    PubMed     Abstract available
    
    
    
86. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence.
    Clin Res Hepatol Gastroenterol. 2022;46:102034.
    PubMed    
    
    
    
87. SU Y, Xie R, Xu Q
    LncRNA THAP9-AS1 highly expressed in tissues of hepatocellular carcinoma and accelerates tumor cell proliferation.
    Clin Res Hepatol Gastroenterol. 2022;46:102025.
    PubMed     Abstract available
    
    
    
88. MOHAMED MMG, Osman A, El-Halawany H
    Plasma exchange for patients with acute or acute on chronic liver failure; meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:102014.
    PubMed    
    
    
    
89. ZHANG X, Song W, Zhang M, Song Y, et al
    Identification of differentially expressed miRNAs and key genes involved in the progression of alcoholic fatty liver disease using rat models.
    Clin Res Hepatol Gastroenterol. 2022;46:102012.
    PubMed     Abstract available
    
    
    
90. ZHAO E, Chen S
    Association of serum C-peptide with all-cause and cardiovascular disease mortality in ultrasound-defined nonalcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:102002.
    PubMed     Abstract available
    
    
    
91. DANIEL-ROBIN T, Benichou B, Leboucher C, Blein C, et al
    Epidemiology, treatment and burden of Wilson disease in France: A 10-year analysis of the national health insurance database.
    Clin Res Hepatol Gastroenterol. 2022;46:101992.
    PubMed     Abstract available
    
    
    
92. LIU T, Yuan Z, Wang H, Wang J, et al
    Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.
    Clin Res Hepatol Gastroenterol. 2022;46:101835.
    PubMed     Abstract available
    
    
    November 2022
93. LI N, Yang P, Fang J
    Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:102022.
    PubMed     Abstract available
    
    
    
94. WASUWANICH P, Choudry H, So JM, Lowry S, et al
    Vanishing bile duct syndrome after drug-induced liver injury.
    Clin Res Hepatol Gastroenterol. 2022;46:102015.
    PubMed     Abstract available
    
    
    
95. SHARMA D, Mandal P
    NAFLD: genetics and its clinical implications.
    Clin Res Hepatol Gastroenterol. 2022;46:102003.
    PubMed     Abstract available
    
    
    
96. WU L, Yang J, Ke RS, Liu Y, et al
    Impact of lncRNA SOX9-AS1 overexpression on the prognosis and progression of intrahepatic cholangiocarcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101999.
    PubMed     Abstract available
    
    
    
97. ISSA Z, Gohy S, Zech F, Baldin P, et al
    Prevalence and characteristics of cystic fibrosis liver disease: a study highlighting the lack of histological diagnosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101977.
    PubMed     Abstract available
    
    
    
98. FANG Z, Yang H, Mao Y
    Letter to the editor: Liver transarterial chemoembolization plus sunitinib for unresectable hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101984.
    PubMed    
    
    
    
99. GUILLAUD O, Woimant F, Couchonnal E, Dumortier J, et al
    Maintenance therapy simplification using a single daily dose: A preliminary real-life feasibility study in patients with Wilson disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101978.
    PubMed     Abstract available
    
    
    October 2022
100. WANG J, Lun W, Shi W
     Effects of elevated bile acid levels on fetal myocardium in intrahepatic cholestasis of pregnancy, a retrospective study from a neonatal perspective.
     Clin Res Hepatol Gastroenterol. 2022;46:102013.
     PubMed     Abstract available
     
     
     
101. QIU JJ, Wei GF, Du JL, Guo J, et al
     Advances in the application of different anesthetic methods and drugs in interventional therapy for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101982.
     PubMed     Abstract available
     
     
     
102. STEENSIG K, Pareek M, Krarup AL, Sogaard P, et al
     Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101952.
     PubMed     Abstract available
     
     
     
103. DING Y, Jiang L, Wang Q, Zhao W, et al
     The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
     Clin Res Hepatol Gastroenterol. 2022;46:101951.
     PubMed     Abstract available
     
     
     
104. BOGOVIC N, Doenecke A, Hart C, Lurken L, et al
     Covid19 vaccination-associated portal vein thrombosis-An interdisciplinary clinical challenge.
     Clin Res Hepatol Gastroenterol. 2022;46:101932.
     PubMed     Abstract available
     
     
     
105. JAIN A, Sobotka LA, Wellner MR
     A rare mimicker of hepatocellular carcinoma: Syphilis.
     Clin Res Hepatol Gastroenterol. 2022;46:101919.
     PubMed    
     
     
     
106. BRAN DM, Fuks D, Lansier A, Gallois C, et al
     Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
     Clin Res Hepatol Gastroenterol. 2022;46:101920.
     PubMed    
     
     
     
107. THABUT D, Weil D, Bouzbib C, Rudler M, et al
     Non-invasive diagnosis and follow-up of portal hypertension.
     Clin Res Hepatol Gastroenterol. 2022;46:101767.
     PubMed     Abstract available
     
     
     August 2022
108. SOURIANARAYANANE A, McCullough AJ
     Accuracy of steatosis and fibrosis NAFLD scores in relation to vibration controlled transient elastography: An NHANES analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101997.
     PubMed     Abstract available
     
     
     
109. SHI Q, Wang F, Du N, Zhou Y, et al
     Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study.
     Clin Res Hepatol Gastroenterol. 2022;46:101986.
     PubMed     Abstract available
     
     
     
110. SALTEL F, Blanc JF
     Hepatocellular carcinoma treatments: A new hope, but a headache for clinicians and researchers.
     Clin Res Hepatol Gastroenterol. 2022;46:101927.
     PubMed    
     
     
     
111. CHEN SQ, He K, Xiao XL
     Multifocal nodular fatty infiltration of the liver: A donut-shaped appearance.
     Clin Res Hepatol Gastroenterol. 2022;46:101985.
     PubMed    
     
     
     
112. DIAS E, Cardoso H, Pacheco J, Lopes J, et al
     Ciliated hepatic foregut cyst: An uncommon cystic liver lesion.
     Clin Res Hepatol Gastroenterol. 2022;46:101949.
     PubMed    
     
     
     
113. ZAFAR Y, Rashid AM, Siddiqi AK, Ellahi A, et al
     Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101970.
     PubMed     Abstract available
     
     
     
114. CALES P, Ravaioli F, Berger A, Farcau O, et al
     Comparison of screening strategies with two new tests to score and diagnose varices needing treatment.
     Clin Res Hepatol Gastroenterol. 2022;46:101925.
     PubMed     Abstract available
     
     
     June 2022
115. NAYAGAM JS, Mandour MO, Taylor A, Heneghan MA, et al
     Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.
     Clin Res Hepatol Gastroenterol. 2022 Jun 18:101980.
     PubMed     Abstract available
     
     
     
116. ADDEO P, Foguenne M, Michard B, Artzner T, et al
     Emergency reversal of a Roux-en-Y Gastric bypass to rescue liver graft from recurrent steatohepatitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101971.
     PubMed    
     
     
     
117. CHOU TP, Hu JT, Hung CS, Chen HY, et al
     Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor.
     Clin Res Hepatol Gastroenterol. 2022;46:101931.
     PubMed    
     
     
     
118. BARBIER L, Cauchy F
     What assessment of the liver before resection for hepatocellular carcinoma?
     Clin Res Hepatol Gastroenterol. 2022;46:101916.
     PubMed    
     
     
     
119. LIU X, Luo J, Zhang L, Yang F, et al
     SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization.
     Clin Res Hepatol Gastroenterol. 2022;46:101897.
     PubMed     Abstract available
     
     
     
120. WANG H, Liu D, Wang C, Yu S, et al
     Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
     Clin Res Hepatol Gastroenterol. 2022;46:101869.
     PubMed     Abstract available
     
     
     May 2022
121. MOREIRA-SILVA H, Amorim J, Santos-Silva E
     Incidental Liver Lesions in children: A practical and evidence-based approach.
     Clin Res Hepatol Gastroenterol. 2022;46:101904.
     PubMed     Abstract available
     
     
     
122. ELGENIDY A, Afifi AM, Awad AK, Jalal PK, et al
     Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101909.
     PubMed    
     
     
     
123. SHI Q, Liu J, Li T, Zhou C, et al
     Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101893.
     PubMed     Abstract available
     
     
     
124. BOULOUTA A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, et al
     The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.
     Clin Res Hepatol Gastroenterol. 2022;46:101896.
     PubMed     Abstract available
     
     
     
125. TRIPON S, Bilbault P, Fabacher T, Lefebvre N, et al
     Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19.
     Clin Res Hepatol Gastroenterol. 2022;46:101894.
     PubMed     Abstract available
     
     
     
126. YOU Y, Hu S
     Aberrant expression of the esophageal carcinoma related gene 4 as a prognostic signature for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101891.
     PubMed     Abstract available
     
     
     
127. ZHAO Y, Zhang C, Zhang Y, Bo C, et al
     Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients.
     Clin Res Hepatol Gastroenterol. 2022;46:101889.
     PubMed     Abstract available
     
     
     April 2022
128. BOILLOT O, Chopinet S, Gregoire E, Milot L, et al
     Partial splenectomy in children undergoing liver transplantation or venous shunt for severe hypersplenism: a case control comparative study.
     Clin Res Hepatol Gastroenterol. 2022 Apr 21:101929.
     PubMed     Abstract available
     
     
     
129. WARASNHE K, Ozcay F, Aydin HI, Ozgun G, et al
     A Novel Mutation in TRMT5 Associated with Idiopathic Non-Cirrhotic Portal Hypertension and Hepatopulmonary Syndrome: Case Report of Two Siblings.
     Clin Res Hepatol Gastroenterol. 2022 Apr 20:101928.
     PubMed     Abstract available
     
     
     
130. SUN L, Deng C, Gu Y, He Y, et al
     Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
     Clin Res Hepatol Gastroenterol. 2022;46:101876.
     PubMed     Abstract available
     
     
     
131. ZHANG X, Jiang M, Zhang X, Zhang J, et al
     An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101877.
     PubMed     Abstract available
     
     
     
132. JAIN A, Kirkpatrick RB, Sobotka LA
     Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
     Clin Res Hepatol Gastroenterol. 2022;46:101875.
     PubMed    
     
     
     
133. LI L, Xin Y, Zhang X, Chen Y, et al
     The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
     Clin Res Hepatol Gastroenterol. 2022;46:101878.
     PubMed     Abstract available
     
     
     
134. HOORNAERT E, Yombi JC, Coubeau L, Baldin P, et al
     Liver hypodense infectious lesions: Is it only bacteria, parasites or fungi?
     Clin Res Hepatol Gastroenterol. 2022;46:101872.
     PubMed    
     
     
     
135. WASUWANICH P, So JM, Scheimann AO, Spahic H, et al
     Hepatic and non-hepatic hydrothorax in pediatric ascites.
     Clin Res Hepatol Gastroenterol. 2022;46:101868.
     PubMed     Abstract available
     
     
     
136. ARTRU F, Moschouri E, Denys A
     Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
     Clin Res Hepatol Gastroenterol. 2022;46:101858.
     PubMed     Abstract available
     
     
     
137. WANG H, He X, Fang D, Wang X, et al
     Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
     Clin Res Hepatol Gastroenterol. 2022;46:101853.
     PubMed     Abstract available
     
     
     
138. ZHANG S, Zhao Y, He L, Bo C, et al
     Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101851.
     PubMed     Abstract available
     
     
     
139. CANIVET CM, Smati S, Lannes A, Brisseau J, et al
     Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
     Clin Res Hepatol Gastroenterol. 2022;46:101848.
     PubMed     Abstract available
     
     
     
140. ZHU X, Lin X, Zhang P, Liu Y, et al
     Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study.
     Clin Res Hepatol Gastroenterol. 2022;46:101843.
     PubMed     Abstract available
     
     
     
141. ATHYROS VG, Katsiki N, Mikhailidis DP
     Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101842.
     PubMed    
     
     
     
142. ZHANG C, Zhang B, Chen A, Yin Q, et al
     Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-beta-mediated fibrosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101833.
     PubMed     Abstract available
     
     
     
143. SHAHID A, Cheema HA
     Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
     Clin Res Hepatol Gastroenterol. 2022;46:101826.
     PubMed    
     
     
     
144. LYU T, Yao H, Wang J, Song L, et al
     Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
     Clin Res Hepatol Gastroenterol. 2022;46:101819.
     PubMed     Abstract available
     
     
     
145. FATIMA K, Moeed A, Waqar E, Atif AR, et al
     Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101816.
     PubMed     Abstract available
     
     
     
146. LONCAR Y, Tartrat N, Lastennet D, Lemoine L, et al
     Pulmonary infection after hepatic resection: Associated factors and impact on outcomes.
     Clin Res Hepatol Gastroenterol. 2022;46:101733.
     PubMed     Abstract available
     
     
     March 2022
147. CORDEIRO A, Ribamar A, Ramalho A
     Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
     Clin Res Hepatol Gastroenterol. 2022;46:101807.
     PubMed     Abstract available
     
     
     
148. JU S, Wang W, Chen P, Li F, et al
     Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
     Clin Res Hepatol Gastroenterol. 2022;46:101859.
     PubMed     Abstract available
     
     
     
149. DUMORTIER J, Simon M, Bouhour F
     Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2022;46:101854.
     PubMed    
     
     
     
150. DANA J, Girard M, Franchi-Abella S, Berteloot L, et al
     Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101855.
     PubMed     Abstract available
     
     
     
151. LI J, Huang WF, Zhang JY
     A rare case of duodenal neuroendocrine tumor with hepatic metastasis.
     Clin Res Hepatol Gastroenterol. 2022;46:101850.
     PubMed    
     
     
     
152. TANG J, Chen C, Zhou M, Wang J, et al
     NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis.
     Clin Res Hepatol Gastroenterol. 2022;46:101847.
     PubMed    
     
     
     
153. VALTIS YK, Barlowe T, Young JH, Lichtman AH, et al
     A woman presenting with an unusual cause of fulminant liver failure and sepsis.
     Clin Res Hepatol Gastroenterol. 2022;46:101836.
     PubMed     Abstract available
     
     
     
154. WU D, Zhang R, Zhan L
     Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile.
     Clin Res Hepatol Gastroenterol. 2022;46:101812.
     PubMed     Abstract available
     
     
     
155. TANG J, Huang Z, Xu J, Lv Q, et al
     Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
     Clin Res Hepatol Gastroenterol. 2022;46:101814.
     PubMed     Abstract available
     
     
     
156. SCHAEFER A, Journaux M, Mourabit HE, Mouri S, et al
     A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy.
     Clin Res Hepatol Gastroenterol. 2022;46:101801.
     PubMed     Abstract available
     
     
     
157. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
     Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
     Clin Res Hepatol Gastroenterol. 2022;46:101800.
     PubMed     Abstract available
     
     
     
158. CAI Y, Wu D, Zhan L
     CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101796.
     PubMed     Abstract available
     
     
     
159. PAPAEFTHYMIOU A, Koffas A, Laskaratos FM, Epstein O, et al
     Upper gastrointestinal video capsule endoscopy: The state of the art.
     Clin Res Hepatol Gastroenterol. 2022;46:101798.
     PubMed     Abstract available
     
     
     February 2022
160. THOMAS LS, Geoffroy V, Patrick C, Rodolphe A, et al
     Infectious complications of portal biliopathy leading to liver transplantation.
     Clin Res Hepatol Gastroenterol. 2022 Feb 10:101879.
     PubMed    
     
     
     
161. KAPS L, Hildebrand K, Nagel M, Michel M, et al
     Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.
     Clin Res Hepatol Gastroenterol. 2022 Feb 3:101873.
     PubMed     Abstract available
     
     
     
162. DU M, Yang S, Liu M, Liu J, et al
     COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
     Clin Res Hepatol Gastroenterol. 2022;46:101793.
     PubMed     Abstract available
     
     
     
163. MACEDO MB, Giardini HAM, Pereira RMR
     A retracted diagnosis-when liver capsule retraction is not what it seems.
     Clin Res Hepatol Gastroenterol. 2022;46:101823.
     PubMed    
     
     
     
164. VITELLIUS C, Paisant A, Lannes A, Chaigneau J, et al
     Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses.
     Clin Res Hepatol Gastroenterol. 2022;46:101797.
     PubMed     Abstract available
     
     
     
165. HE S, Chen W, Yang Y, Tang X, et al
     Adult diffuse hepatic hemangiomatosis: A case report and review of the literature.
     Clin Res Hepatol Gastroenterol. 2022;46:101789.
     PubMed     Abstract available
     
     
     
166. WANG L, Peng Y, Qian Y, Liu Z, et al
     Transjugular extrahepatic portosystemic shunt (TEPS) creation in patients with complete occlusion of portal vein: Primary experience in a single medical center.
     Clin Res Hepatol Gastroenterol. 2022;46:101786.
     PubMed    
     
     
     
167. CAMPION B, Larrey E, Wagner M, Rudler M, et al
     Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage a trois" !
     Clin Res Hepatol Gastroenterol. 2022;46:101785.
     PubMed    
     
     
     
168. HUANG L, Liu J, Bie C, Liu H, et al
     Advances in cell death - related signaling pathways in acute-on-chronic liver failure.
     Clin Res Hepatol Gastroenterol. 2022;46:101783.
     PubMed     Abstract available
     
     
     
169. LI Q, Xu H, Sui C, Zhang H, et al
     Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
     Clin Res Hepatol Gastroenterol. 2022;46:101781.
     PubMed     Abstract available
     
     
     January 2022
170. XIN H, Zhang C, Ding Z, Zhang M, et al
     TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
     Clin Res Hepatol Gastroenterol. 2022;46:101777.
     PubMed    
     
     
     
171. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
     Non-invasive diagnosis and follow-up of benign liver tumours.
     Clin Res Hepatol Gastroenterol. 2022;46:101765.
     PubMed     Abstract available
     
     
     
172. DE LEDINGHEN V
     Non-invasive diagnosis and follow-up of chronic liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101763.
     PubMed    
     
     
     
173. NAHON P, Aube C, Moga L, Chalaye J, et al
     Non-invasive diagnosis and follow-up of primary malignant liver tumours.
     Clin Res Hepatol Gastroenterol. 2022;46:101766.
     PubMed     Abstract available
     
     
     
174. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
     Non-invasive diagnosis and follow-up of primary biliary cholangitis.
     Clin Res Hepatol Gastroenterol. 2022;46:101770.
     PubMed     Abstract available
     
     
     
175. BOURSIER J, Guillaume M, Bouzbib C, Lannes A, et al
     Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101769.
     PubMed     Abstract available
     
     
     
176. RAUTOU PE, Elkrief L, Decraecker M, Ollivier-Hourmand I, et al
     Non-invasive diagnosis and follow-up of vascular liver diseases.
     Clin Res Hepatol Gastroenterol. 2022;46:101764.
     PubMed     Abstract available
     
     
     
177. SOBESKY R, Guillaud O, Bouzbib C, Sogni P, et al
     Non-invasive diagnosis and follow-up of rare genetic liver diseases.
     Clin Res Hepatol Gastroenterol. 2022;46:101768.
     PubMed     Abstract available
     
     
     
178. BOURSIER J, Decraecker M, Bourliere M, Bureau C, et al
     Quality criteria for the measurement of liver stiffness.
     Clin Res Hepatol Gastroenterol. 2022;46:101761.
     PubMed     Abstract available
     
     
     
179. CHEN BR, Pan CQ
     Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2022;46:101755.
     PubMed     Abstract available
     
     
     
180. STEMPAK-DROISSART T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al
     Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.
     Clin Res Hepatol Gastroenterol. 2022;46:101756.
     PubMed     Abstract available
     
     
     
181. HOUNTONDJI L, Debourdeau A, Meunier L
     Acute liver failure secondary to Langerhans cell histiocytosis.
     Clin Res Hepatol Gastroenterol. 2022;46:101744.
     PubMed    
     
     
     
182. ZIMMER V, Emrich K
     Nodular gastric antral vascular ectasia: Distinct portal hypertensive hyperplastic polyp lesions.
     Clin Res Hepatol Gastroenterol. 2022;46:101745.
     PubMed    
     
     
     
183. DU J, Zhang J, Chen X, Zhang S, et al
     Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients.
     Clin Res Hepatol Gastroenterol. 2022;46:101697.
     PubMed     Abstract available
     
     
     December 2021
184. BORIE F, Dubray V, Tretarre B
     Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.
     Clin Res Hepatol Gastroenterol. 2021 Dec 25:101856.
     PubMed     Abstract available
     
     
     November 2021
185. SOBOTKA LA, Mumtaz K, Hinton A, Conteh LF, et al
     The Time to Advocate for Influenza Vaccines in Patients with Cirrhosis is Now.
     Clin Res Hepatol Gastroenterol. 2021 Nov 20:101838.
     PubMed     Abstract available
     
     
     
186. MOREIRA JLS, Barbosa SMB, Goncalves Junior J
     Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review.
     Clin Res Hepatol Gastroenterol. 2021;45:101752.
     PubMed     Abstract available
     
     
     
187. THOEN RU, Longo L, Neto SC, Alvares-da-Silva MR, et al
     Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2021;45:101638.
     PubMed     Abstract available
     
     
     
188. RUTHER DF, Sebode M, Lohse AW, Wernicke S, et al
     Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER.
     Clin Res Hepatol Gastroenterol. 2021;45:101760.
     PubMed     Abstract available
     
     
     
189. TUTUNCHI H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, et al
     Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
     Clin Res Hepatol Gastroenterol. 2021;45:101754.
     PubMed     Abstract available
     
     
     
190. ZHAO J, Wang Y, Su H, Su L, et al
     Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review.
     Clin Res Hepatol Gastroenterol. 2021;45:101736.
     PubMed     Abstract available
     
     
     
191. BLAISE L, Pereira H, Vilgrain V, Sutter O, et al
     Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
     Clin Res Hepatol Gastroenterol. 2021;45:101731.
     PubMed     Abstract available
     
     
     
192. WONG YJ, Kew GS, Tan PS, Chen Z, et al
     Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study.
     Clin Res Hepatol Gastroenterol. 2021;45:101598.
     PubMed     Abstract available
     
     
     
193. MOTAMED N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, et al
     The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study.
     Clin Res Hepatol Gastroenterol. 2021;45:101567.
     PubMed     Abstract available
     
     
     
194. BOUZBIB C, Cluzel P, Sultanik P, Bernard-Chabert B, et al
     Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
     Clin Res Hepatol Gastroenterol. 2021;45:101593.
     PubMed     Abstract available
     
     
     
195. HOU H, Chen D, Liu J, Feng L, et al
     Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
     Clin Res Hepatol Gastroenterol. 2021;45:101623.
     PubMed     Abstract available
     
     
     
196. GE J, Zhang X, Zhang B, Zhu L, et al
     Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101573.
     PubMed     Abstract available
     
     
     
197. LI X, Yu Y, Liu L
     Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101545.
     PubMed     Abstract available
     
     
     
198. VEYRE F, Dumortier J, Radenne S, Valette PJ, et al
     Rare isolated spontaneous hepatic artery thrombosis in a non-transplant patient.
     Clin Res Hepatol Gastroenterol. 2021;45:101453.
     PubMed    
     
     
     
199. VANDE BERG P, Borbath I, Baldin P, Vande Berg D, et al
     Granuloma formation within perihepatic lymphadenopathy.
     Clin Res Hepatol Gastroenterol. 2021;45:101504.
     PubMed    
     
     
     
200. ABDI SAH, Shukla S, Khan J, Al Zahrani A, et al
     Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101443.
     PubMed    
     
     
     October 2021
201. ZHANG L, Zhou Y, Zhang J
     An incidental hepatic lesion in a cirrhotic liver.
     Clin Res Hepatol Gastroenterol. 2021 Oct 28:101825.
     PubMed    
     
     
     
202. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
     Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
     Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
     PubMed     Abstract available
     
     
     
203. ARTZNER T, Legeai C, Antoine C, Jasseron C, et al
     Liver transplantation for critically ill cirrhotic patients: results from the French transplant registry.
     Clin Res Hepatol Gastroenterol. 2021 Oct 1:101817.
     PubMed     Abstract available
     
     
     September 2021
204. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
     Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
     Clin Res Hepatol Gastroenterol. 2021;45:101556.
     PubMed     Abstract available
     
     
     
205. MALEZIEUX E, Meunier L, Riviere B, Larrey D, et al
     Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI.
     Clin Res Hepatol Gastroenterol. 2021;45:101599.
     PubMed     Abstract available
     
     
     
206. CHEN S, Zhao E
     Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101587.
     PubMed     Abstract available
     
     
     
207. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
     Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
     Clin Res Hepatol Gastroenterol. 2021;45:101751.
     PubMed     Abstract available
     
     
     
208. WAHLIN S, Andersson J
     Liver health literacy and social stigma of liver disease: A general population e-survey.
     Clin Res Hepatol Gastroenterol. 2021;45:101750.
     PubMed     Abstract available
     
     
     
209. LI X, Yao Q, Li R, Jin Y, et al
     Isoflurane induces liver injury by modulating the expression of miR-125a-5p.
     Clin Res Hepatol Gastroenterol. 2021;45:101732.
     PubMed     Abstract available
     
     
     
210. BENARD J, Lafrance MJ, Gordien E, Amaral L, et al
     Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
     Clin Res Hepatol Gastroenterol. 2021;45:101706.
     PubMed    
     
     
     
211. YANG M, Wei S, Zhao H, Zhou D, et al
     The role of miRNA125b in the progression of hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101712.
     PubMed     Abstract available
     
     
     
212. LUO L, He X, Li K, Long Y, et al
     Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101581.
     PubMed     Abstract available
     
     
     
213. YANG D, Wu H, Nong W, Zheng M, et al
     A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101509.
     PubMed     Abstract available
     
     
     
214. DE SOUSA MAGALHAES R, Xavier S, Magalhaes J, Rosa B, et al
     Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101580.
     PubMed     Abstract available
     
     
     
215. BOEKEN T, Gallois C, Douard R, Meatchi T, et al
     Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.
     Clin Res Hepatol Gastroenterol. 2021;45:101557.
     PubMed    
     
     
     August 2021
216. LARREY E, Cluzel P, Rudler M, Goumard C, et al
     (TIPS for patients with early HCC: a bridge to liver transplantation).
     Clin Res Hepatol Gastroenterol. 2021 Aug 13:101790.
     PubMed     Abstract available
     
     
     
217. BOUZBIB C, El Mourabit H, Wendum D, Lasnier E, et al
     ATP-binding cassette transporters expression in rats with cirrhosis and hepatic encephalopathy.
     Clin Res Hepatol Gastroenterol. 2021 Aug 9:101784.
     PubMed     Abstract available
     
     
     July 2021
218. DUMORTIER J, Besch C, Moga L, Coilly A, et al
     NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.
     Clin Res Hepatol Gastroenterol. 2021 Jul 28:101774.
     PubMed     Abstract available
     
     
     
219. VILLERET F, Dumortier J, Erard-Poinsot D
     How will NAFLD change the liver transplant landscape in the 2020s?
     Clin Res Hepatol Gastroenterol. 2021 Jul 23:101759.
     PubMed     Abstract available
     
     
     
220. LANTHIER N, Starkel P, Dahlqvist G
     Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?
     Clin Res Hepatol Gastroenterol. 2021;45:101721.
     PubMed     Abstract available
     
     
     
221. LIU W, Xu C, Meng Q, Kang P, et al
     The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101527.
     PubMed     Abstract available
     
     
     
222. CAMPOS-MURGUIA A, Valdez-Hernandez P, Cordova-Gallardo J, Arteaga-Vazquez J, et al
     Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort.
     Clin Res Hepatol Gastroenterol. 2021;45:101519.
     PubMed     Abstract available
     
     
     
223. KIM KM, Roh JH, Lee S, Yoon JH, et al
     Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
     Clin Res Hepatol Gastroenterol. 2021;45:101510.
     PubMed     Abstract available
     
     
     
224. CAI L, Li H, Guo J, Zhao W, et al
     Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
     Clin Res Hepatol Gastroenterol. 2021;45:101535.
     PubMed     Abstract available
     
     
     
225. SHI JY, Sun LY, Quan B, Xing H, et al
     A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
     Clin Res Hepatol Gastroenterol. 2021;45:101534.
     PubMed     Abstract available
     
     
     
226. IM HJ, Ahn YC, Wang JH, Lee MM, et al
     Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.
     Clin Res Hepatol Gastroenterol. 2021;45:101526.
     PubMed     Abstract available
     
     
     
227. PERRAULT F, Echelard P, Viens D, Borduas M, et al
     Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
     Clin Res Hepatol Gastroenterol. 2021;45:101475.
     PubMed     Abstract available
     
     
     
228. LIU J, Dai XL, Zhou XJ, Gu BH, et al
     Metamizole-induced acute liver failure in a boy.
     Clin Res Hepatol Gastroenterol. 2021;45:101570.
     PubMed    
     
     
     
229. MOSCHOURI E, Hocquelet A, Vermersch M, Fraga M, et al
     DIPS, a safe and effective alternative in patients with unfavorable anatomy to TIPSS: first experience in a tertiary center.
     Clin Res Hepatol Gastroenterol. 2021;45:101715.
     PubMed    
     
     
     
230. COLAK Y, Hasan B, Erkalma B, Tandon K, et al
     Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.
     Clin Res Hepatol Gastroenterol. 2021;45:101710.
     PubMed     Abstract available
     
     
     
231. ILUZ-FREUNDLICH D, Grubert Van Iderstine M, Uhanova J, Zhang M, et al
     Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis.
     Clin Res Hepatol Gastroenterol. 2021;45:101694.
     PubMed     Abstract available
     
     
     June 2021
232. QU Y, Li T, Lin C, Liu F, et al
     Animal Naming Test for the Assessment of Minimal Hepatic Encephalopathy in Asian Cirrhotic Populations.
     Clin Res Hepatol Gastroenterol. 2021 Jun 3:101729.
     PubMed     Abstract available
     
     
     
233. RAZAQ S, Kara M, Ozcakar L
     Measure Grip Strength, Gait Speed and Quadriceps Muscle in Cirrhosis. Comment to "Frailty, sarcopenia and mortality in cirrhosis: What is the best assessment, how to interpret the data correctly and what interventions are possible?"
     Clin Res Hepatol Gastroenterol. 2021 Jun 1:101727.
     PubMed    
     
     
     May 2021
234. VUJAKLIJA BRAJKOVIC A, Zlopasa O, Gubarev Vrdoljak N, Goran T, et al
     Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19.
     Clin Res Hepatol Gastroenterol. 2021;45:101678.
     PubMed    
     
     
     
235. SERRA F, Bonaduce I, De Ruvo N, Cautero N, et al
     Covid-19 and hepatic injury: A systematic review.
     Clin Res Hepatol Gastroenterol. 2021;45:101605.
     PubMed    
     
     
     
236. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
     HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
     Clin Res Hepatol Gastroenterol. 2021;45:101608.
     PubMed    
     
     
     
237. WORLAND T, O'Neill P, Rusli F
     Resolution of metastatic hepatocellular carcinoma with sour cherry intake.
     Clin Res Hepatol Gastroenterol. 2021;45:101663.
     PubMed    
     
     
     
238. DEVICTOR J, Leclercq A, Hazo JB, Burnet E, et al
     Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey.
     Clin Res Hepatol Gastroenterol. 2021;45:101650.
     PubMed     Abstract available
     
     
     
239. MU X, Tong J, Xu X, Chen J, et al
     World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101548.
     PubMed     Abstract available
     
     
     
240. ARAZ M, Kilinc F, Kerimoglu U, Keskin M, et al
     Irinotecan-induced NASH and liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101606.
     PubMed    
     
     
     
241. KALOGIROU MS, Patoulias D, Haidich AB, Akriviadis E, et al
     Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
     Clin Res Hepatol Gastroenterol. 2021;45:101568.
     PubMed     Abstract available
     
     
     
242. LIN M, Zeng H, Deng G, Lei J, et al
     Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101530.
     PubMed     Abstract available
     
     
     
243. KARNSAKUL W, Wasuwanich P, Ingviya T, Laengvejkal P, et al
     Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites.
     Clin Res Hepatol Gastroenterol. 2021;45:101549.
     PubMed     Abstract available
     
     
     
244. KARATAS E, Bouchecareilh M
     Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease.
     Clin Res Hepatol Gastroenterol. 2021;45:101538.
     PubMed    
     
     
     
245. DE MUNCK TJI, Verhaegh P, Lodewick T, Bakers F, et al
     Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
     Clin Res Hepatol Gastroenterol. 2021;45:101500.
     PubMed     Abstract available
     
     
     
246. DE VOS N, Van der Meulen J, Van Der Linden M, Claes K, et al
     Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review.
     Clin Res Hepatol Gastroenterol. 2021;45:101478.
     PubMed     Abstract available
     
     
     
247. LYKAVIERIS P, Bernard O, Jacquemin E
     Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
     Clin Res Hepatol Gastroenterol. 2021;45:101472.
     PubMed    
     
     
     
248. RIVAS M, Aguiar T, Fernandes G, Lemes R, et al
     DNA methylation as a key epigenetic player for hepatoblastoma characterization.
     Clin Res Hepatol Gastroenterol. 2021;45:101684.
     PubMed     Abstract available
     
     
     
249. BOILLOT O, Cayot B, Guillaud O, Crozet-Chaussin J, et al
     Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.
     Clin Res Hepatol Gastroenterol. 2021;45:101670.
     PubMed     Abstract available
     
     
     
250. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
     Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101675.
     PubMed     Abstract available
     
     
     
251. ZAREBSKA I, Gzil A, Durslewicz J, Jaworski D, et al
     The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.
     Clin Res Hepatol Gastroenterol. 2021;45:101664.
     PubMed     Abstract available
     
     
     April 2021
252. OZCELIK F
     Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters.
     Clin Res Hepatol Gastroenterol. 2021 Apr 27:101708.
     PubMed    
     
     
     
253. CARDOSO CC, Matiollo C, Pereira CHJ, Fonseca JS, et al
     B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis.
     Clin Res Hepatol Gastroenterol. 2021 Apr 11:101698.
     PubMed     Abstract available
     
     
     March 2021
254. TORNAI D, Vitalis Z, Jonas A, Janka T, et al
     Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
     Clin Res Hepatol Gastroenterol. 2021;45:101579.
     PubMed     Abstract available
     
     
     
255. CAO X, Cao Z, Ou C, Zhang L, et al
     Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101583.
     PubMed     Abstract available
     
     
     
256. CORPECHOT C
     The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
     Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.
     PubMed    
     
     
     
257. ALTIERI M, Seree O, Lobbedez T, Segol P, et al
     Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101514.
     PubMed     Abstract available
     
     
     
258. LANTHIER N, Starkel P, Dahlqvist G
     Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?
     Clin Res Hepatol Gastroenterol. 2021 Mar 2:101661.
     PubMed     Abstract available
     
     
     
259. COUPIER A, Pioche M, Steer N, Zoulim F, et al
     An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
     Clin Res Hepatol Gastroenterol. 2021 Mar 2:101662.
     PubMed    
     
     
     
260. BLANC JF, Debaillon-Vesque A, Roth G, Barbare JC, et al
     Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
     Clin Res Hepatol Gastroenterol. 2021;45:101590.
     PubMed     Abstract available
     
     
     
261. TIAN J, Hu D
     LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
     Clin Res Hepatol Gastroenterol. 2021;45:101490.
     PubMed     Abstract available
     
     
     
262. SOBOTKA LA, Chen JL, Wellner MR
     Compression induced hepatic injury: an unusual case of abnormal liver function tests.
     Clin Res Hepatol Gastroenterol. 2021;45:101655.
     PubMed    
     
     
     
263. LIU Y, Wu H, Wang Z, Wu J, et al
     Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
     Clin Res Hepatol Gastroenterol. 2021;45:101312.
     PubMed     Abstract available
     
     
     
264. SU Q, Wang H
     Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.
     Clin Res Hepatol Gastroenterol. 2021;45:101648.
     PubMed     Abstract available
     
     
     
265. ROSSO C, Caviglia GP, Armandi A, Ribaldone DG, et al
     Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
     Clin Res Hepatol Gastroenterol. 2021;45:101611.
     PubMed    
     
     
     
266. XIE Z, Wu Y, Liu S, Lai Y, et al
     LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis.
     Clin Res Hepatol Gastroenterol. 2021;45:101469.
     PubMed     Abstract available
     
     
     
267. MAZZOLA A, Magro B, Perdigao F, Charlotte F, et al
     Acute liver failure and HELLP syndrome: A clinical case and literature review.
     Clin Res Hepatol Gastroenterol. 2021;45:101498.
     PubMed     Abstract available
     
     
     
268. SHEN X, Huang Y, Guo H, Peng H, et al
     Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
     Clin Res Hepatol Gastroenterol. 2021;45:101495.
     PubMed     Abstract available
     
     
     
269. XU X, Hou Z, Xu Y, Gu H, et al
     The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101482.
     PubMed     Abstract available
     
     
     
270. CHEN C, Qiu H, Yao Y, Zhang Z, et al
     Comprehensive predictive factors for CalliSpheres(R) microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101460.
     PubMed     Abstract available
     
     
     
271. TURPIN A, de Baere T, Heurgue A, Le Malicot K, et al
     Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
     Clin Res Hepatol Gastroenterol. 2021;45:101464.
     PubMed     Abstract available
     
     
     February 2021
272. GAO Y, Liu H, Tang F, Zhang X, et al
     Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021 Feb 15:101649.
     PubMed     Abstract available
     
     
     January 2021
273. ZHAO N, Liu X, Guo H, Zhao X, et al
     Interleukin-35: An emerging player in the progression of liver diseases.
     Clin Res Hepatol Gastroenterol. 2021;45:101518.
     PubMed     Abstract available
     
     
     
274. CHARPY F, Debourdeau A, Boivineau L, Meszaros M, et al
     Hepatic amyloidosis as a case of fatal fulminant liver failure.
     Clin Res Hepatol Gastroenterol. 2021;45:101506.
     PubMed    
     
     
     
275. BRAUNER C, Joveleviths D, Alvares-da-Silva MR
     Hepatotoxicity by methyl methacrylate.
     Clin Res Hepatol Gastroenterol. 2021;45:101513.
     PubMed    
     
     
     
276. THEVENOT T, Savale L, Sitbon O
     Portopulmonary hypertension: An unfolding story.
     Clin Res Hepatol Gastroenterol. 2021;45:101492.
     PubMed    
     
     
     
277. WANG J, Feng L, Zhang L
     Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.
     Clin Res Hepatol Gastroenterol. 2021;45:101440.
     PubMed     Abstract available
     
     
     
278. LEMAITRE C, Thiebaut PA, Francois A, Michel P, et al
     An unexpected cause of heterogeneous liver.
     Clin Res Hepatol Gastroenterol. 2021;45:101444.
     PubMed    
     
     
     
279. KANG Y, Park S, Kim S, Han SJ, et al
     Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
     Clin Res Hepatol Gastroenterol. 2021;45:101437.
     PubMed     Abstract available
     
     
     
280. RAFFETTI E, Portolani N, Molfino S, Mentasti S, et al
     Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.
     Clin Res Hepatol Gastroenterol. 2021;45:101433.
     PubMed     Abstract available
     
     
     
281. CHANG Y, He J, Xiang X, Li H, et al
     LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients.
     Clin Res Hepatol Gastroenterol. 2021;45:101435.
     PubMed     Abstract available
     
     
     November 2020
282. HUANG C, Seah JJ, Tan CK, Kam JW, et al
     Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2020 Nov 29:101528.
     PubMed     Abstract available
     
     
     August 2020
283. ELKRIEF L, Houssel-Debry P, Ackermann O, Franchi-Abella S, et al
     Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction.
     Clin Res Hepatol Gastroenterol. 2020 Aug 17. pii: S2210-7401(20)30091.
     PubMed     Abstract available
     
     
     July 2020
284. TRIPON S, Mayer P, Svab A, Habersetzer F, et al
     Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
     Clin Res Hepatol Gastroenterol. 2020 Jul 9. pii: S2210-7401(20)30181.
     PubMed     Abstract available
     
     
     April 2020
285. ABERGEL A, Gasperment M, Nery FG, Buchard B, et al
     Extrahepatic portal vein obstruction (EHPVO) in cirrhosis.
     Clin Res Hepatol Gastroenterol. 2020 Apr 17. pii: S2210-7401(20)30089.
     PubMed    
     
     
     
286. JANKOWSKA I, Czubkowski P, Rokicki D, Lipinski P, et al
     Acute liver failure due to DGUOK deficiency-is liver transplantation justified?
     Clin Res Hepatol Gastroenterol. 2020 Apr 8. pii: S2210-7401(20)30082.
     PubMed     Abstract available
     
     
     March 2020
287. FELLI E, Baumert T, Pessaux P
     Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
     Clin Res Hepatol Gastroenterol. 2020 Mar 18. pii: S2210-7401(20)30049.
     PubMed    
     
     
     
288. MORANDEAU E, Rayer C, Jezequel C, Guyader D, et al
     Hepatic encephalopathy post liver transplantation.
     Clin Res Hepatol Gastroenterol. 2020 Mar 10. pii: S2210-7401(20)30039.
     PubMed    
     
     
     January 2020
289. PETA V, Zhu J, Lubman DM, Huguet S, et al
     Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
     Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
     PubMed     Abstract available
     
     
     
290. HEDJOUDJE A, Cervoni JP, Patry C, Chatot M, et al
     Takotsubo cardiomyopathy triggered by delirium tremens in a cirrhotic patient with acute-on-chronic liver failure: A case report.
     Clin Res Hepatol Gastroenterol. 2020 Jan 9. pii: S2210-7401(19)30262.
     PubMed     Abstract available
     
     
     November 2019
291. ALLAIRE M, Cadranel JF, Nguyen TTN, Garioud A, et al
     Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
     Clin Res Hepatol Gastroenterol. 2019 Nov 6. pii: S2210-7401(19)30224.
     PubMed     Abstract available
     
     
     October 2019
292. ALLAIRE M, Walter A, Sutter O, Nahon P, et al
     TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
     Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217.
     PubMed     Abstract available
     
     
     June 2019
293. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
     Primary biliary cholangitis in patients with inflammatory bowel disease.
     Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.